- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02100072
Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis
December 10, 2020 updated by: Cynosure, Inc.
The purpose of this study is to evaluate the safety and efficacy of the Nd:YAG 1440 nm wavelength laser for the treatment of primary hyperhidrosis of the axilla.
Study Overview
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Chestnut Hill, Massachusetts, United States, 02467
- Skin Care Physicians
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A healthy non-smoking male or female between 18-55 years of age
- Understand/accept obligation not to receive any other procedures in anatomical areas exhibiting axillary hyperhidrosis through 3 months prior to treatment
- Understand and accept the obligation and is logistically able to present for all scheduled follow-up visits
- Clinically diagnosed for primary hyperhidrosis of the axilla.
- A self-assessed Hyperhidrosis Disease Severity Scale (HDSS) score of three (3) or four (4)
Exclusion Criteria:
- Clinical diagnosis of secondary hyperhidrosis
- Uncontrolled systemic disease or infection
- Concurrent use of any hyperhidrosis treatments other than over the counter antiperspirants or deodorants
- Receipt of Botox® or Dysport® within the past six months
- Patients who refuse to stop using over the counter antiperspirants 24 hours prior to the day of surgery and each of the follow-up visits at 3 months and 6 months that Minors starch iodine tests may be performed.
- Patients using or having used within 7 days of baseline visit: cholinomimetic agents, anticholinergic agents, prescription antiperspirants, any herbal medicine treatments or any other treatments for hyperhidrosis except over the counter antiperspirant or planning to use such agents during the course of the study.
- Any previous liposuction/liposculpture or any type of surgery for hyperhidrosis; OR any other types of treatments for hyperhidrosis in the area to be treated in the past 6 months
- Has any other medical condition, that, in the investigator's opinion would interfere with the subject's participation in the study
- Is susceptible to light induced seizures or history of seizures
- Has a history of keloid formation
- Significant cardiovascular disease
- Bleeding disorders
- Anti-platelet and anticoagulant medication
- Sensitivity to lidocaine or epinephrine
- Pregnancy or planned pregnancy
- Existing neuromuscular disorders (myasthenia gravis, Eaton-Lambert Syndrome, amyotrophic lateral sclerosis)
- Electronic implants
- Subjects requiring supplemental oxygen
- Has therapies or medications which may interfere with the treatment (including medications causing photosensitivity
- Allergic to Doxycycline
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Nd:YAG 1440 nm laser
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Sweating Assessed Using Gravimetry
Time Frame: Baseline and 3 months post baseline
|
A gravimetry test was performed to determine the quantity of sweat produced, comparing the post-treatment to the baseline numbers.
A pre-weighted filter paper was placed on the armpit, and then weighed afterwards to determine the quantity of sweat produced.
To calculate the change between the baseline and 3 months post baselines, the values taken at these 2 time points are subtracted from each other.
A negative value means that there has been a decrease in gravimetric weight since the baseline.
|
Baseline and 3 months post baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
March 25, 2014
First Submitted That Met QC Criteria
March 27, 2014
First Posted (Estimate)
March 31, 2014
Study Record Updates
Last Update Posted (Actual)
January 8, 2021
Last Update Submitted That Met QC Criteria
December 10, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CYN13-MK-HH01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperhidrosis
-
Atacama TherapeuticsCompletedPalmar HyperhidrosisUnited States
-
Miramar LabsCompletedAxillary HyperhidrosisCanada
-
Commons Aesthetic Plastic SurgerySound Surgical Technologies, LLC.CompletedAxillary HyperhidrosisUnited States
-
Botanix PharmaceuticalsCompletedAxillary HyperhidrosisUnited States
-
miraDry, Inc.Withdrawn
-
Botanix PharmaceuticalsCompletedAxillary HyperhidrosisUnited States
-
Northwestern UniversityCompletedAxillary HyperhidrosisUnited States
-
Ulthera, IncCompletedAxillary HyperhidrosisGermany
-
Peking University People's HospitalBeijing Municipal Science & Technology CommissionCompleted
-
United States Naval Medical Center, San DiegoCandela Corp.Unknown
Clinical Trials on Nd:YAG 1440 nm laser
-
Cynosure, Inc.CompletedSkin Tightening of the Mandibular and Sub-mandibular AreasUnited States
-
Henry Ford Health SystemCompletedHidradenitis SuppurativaUnited States
-
Aalborg University HospitalCompletedOnychomycosis of ToenailDenmark
-
Stanford UniversityCompletedOnychomycosisUnited States
-
University of California, IrvineCandela CorporationCompletedLocalized LipodystrophyUnited States
-
Cutera Inc.WithdrawnLaser Tattoo RemovalCanada
-
Christopher ZacharyRecruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Jason K Rivers, MD, FRCPC, FAADCutera Inc.Completed
-
Bausch Health Americas, Inc.Completed